Invst LLC Raises Stock Position in Alphatec Holdings, Inc. (NASDAQ:ATEC)

Invst LLC lifted its holdings in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) by 3.7% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 158,549 shares of the medical technology company’s stock after buying an additional 5,630 shares during the period. Invst LLC’s holdings in Alphatec were worth $882,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Comerica Bank lifted its stake in shares of Alphatec by 64.8% during the first quarter. Comerica Bank now owns 6,443 shares of the medical technology company’s stock worth $89,000 after purchasing an additional 2,534 shares in the last quarter. Van ECK Associates Corp raised its holdings in shares of Alphatec by 11.8% during the 2nd quarter. Van ECK Associates Corp now owns 12,275 shares of the medical technology company’s stock valued at $128,000 after buying an additional 1,300 shares during the period. XTX Topco Ltd acquired a new position in Alphatec during the 3rd quarter worth approximately $69,000. Cetera Advisors LLC boosted its holdings in Alphatec by 15.6% in the 1st quarter. Cetera Advisors LLC now owns 12,720 shares of the medical technology company’s stock worth $175,000 after acquiring an additional 1,720 shares during the period. Finally, Net Worth Advisory Group purchased a new position in Alphatec in the 3rd quarter worth approximately $76,000. 66.35% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have recently commented on ATEC. HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of Alphatec in a research report on Thursday, October 31st. Lake Street Capital cut their price objective on shares of Alphatec from $32.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, September 3rd. Needham & Company LLC reissued a “buy” rating and issued a $13.00 price objective on shares of Alphatec in a research report on Thursday, October 31st. Barclays lifted their target price on Alphatec from $19.00 to $20.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 19th. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $20.00 price target on shares of Alphatec in a report on Friday, August 30th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $17.11.

Alphatec Trading Up 0.4 %

Shares of NASDAQ ATEC opened at $9.65 on Wednesday. The stock has a market capitalization of $1.37 billion, a P/E ratio of -7.54 and a beta of 1.38. The stock’s 50 day moving average price is $7.72 and its two-hundred day moving average price is $8.13. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21. Alphatec Holdings, Inc. has a 52-week low of $4.88 and a 52-week high of $17.34.

Alphatec Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.